Details

Title
Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein–ACE2 interaction
Author
Lin ChangDong 1 ; Li, Yue 1 ; Zhang YueBin 2   VIAFID ORCID Logo  ; Liu ZhaoYuan 1 ; Xia, Mu 2 ; Gu Chenjian 3 ; Liu, Jing 3 ; Li Yutang 3 ; Li, GuoHui 2 ; Chen, JianFeng 4   VIAFID ORCID Logo 

 University of Chinese Academy of Sciences, State Key Laboratory of Cell Biology, Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China (GRID:grid.410726.6) (ISNI:0000 0004 1797 8419) 
 Chinese Academy of Sciences, State Key Laboratory of Molecular Reaction Dynamics, Dalian Institute of Chemical Physics, Dalian, China (GRID:grid.9227.e) (ISNI:0000000119573309) 
 Fudan University, Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Department of Medical Microbiology and Parasitology, School of Basic Medical Sciences, Shanghai Medical College, Shanghai, China (GRID:grid.8547.e) (ISNI:0000 0001 0125 2443); BSL-3 laboratory of Fudan University, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China (GRID:grid.11841.3d) (ISNI:0000 0004 0619 8943) 
 University of Chinese Academy of Sciences, State Key Laboratory of Cell Biology, Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China (GRID:grid.410726.6) (ISNI:0000 0004 1797 8419); University of Chinese Academy of Sciences, School of Life Science, Hangzhou Institute for Advanced Study, Hangzhou, China (GRID:grid.410726.6) (ISNI:0000 0004 1797 8419) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
ISSN
20959907
e-ISSN
20593635
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2528635570
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.